• Medicina · Jan 2021

    Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology.

    • Ana L Basquiera, Mercedes J García, Juliana Martinez Rolón, Julieta Olmedo, Julia Laviano, Rubén Burgos, Gastón Caeiro, Guillermina Remaggi, Pablo Raña, Mariano Paoletti, Carlos M González, Isolda Fernández, Astrid Pavlovsky, Maria A Perusini, Andrea Rodriguez, Luciana Guanchiale, Analia Carvani, Laura Mandrile, Flavia Figueroa, Angeles Vicente Reparaz, Patricia N Fragapane Mathus, Gonzalo Garate, María E Fauque, Gustavo Kantor, Soledad Cruset, Jacqueline S Gonzalez Lorch, Milagros Szelagowski, María P Giarini, Natalia Oliveira, María C García, María V Ventriglia, Patricio H Pereyra, Daniel R Gutierrez, Gustavo Kusminsky, Josefina Troccoli, María J Freitas, Santiago Cranco, Natalia Del V Sanchez, Irene Rey, María E Funes, Sol Jarchum, Julian Freue, Augusto Miroli, Osvaldo Guerrero, Lisa López Ares, Reinaldo Campestri, Victor Bove, Graciela N Salinas, María Cabrejo, Jorge H Milone, Soledad Zabaljauregui, Daniel Gotta, Juan Carlos Dupont, and German Stemmelin.
    • Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail: ana.basquiera@hospitalprivado.com.ar.
    • Medicina (B Aires). 2021 Jan 1; 81 (4): 536-545.

    AbstractIndividuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…